AbbVie Releases Positive Topline Results from Upadacitinib Study for Giant Cell Arteritis

RINVOQ (upadacitinib) is a Janus Kinase inhibitor that is currently approved to treat a variety of conditions: moderate to severe atopic dermatitis, active psoriatis arthritis, moderate to severe rheumatoid arthritis,…

Continue Reading AbbVie Releases Positive Topline Results from Upadacitinib Study for Giant Cell Arteritis
FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases
source: shutterstock.com

FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases

In early March 2024, Tyler Patchen reported that the U.S. Food and Drug Administration (FDA) approved both intravenous and subcutaneous formulations of Tyenne (tocilizumab-aazg) for use in a variety of…

Continue Reading FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases
New Guidelines for Vasculitis Treatment Recommend First-Line Biologics for Some Patients
source: pixabay.com

New Guidelines for Vasculitis Treatment Recommend First-Line Biologics for Some Patients

According to a story from Healio, new guidelines for the treatment of different forms of vasculitis recommend the use of biologic therapies as a first-line option for certain patients. It…

Continue Reading New Guidelines for Vasculitis Treatment Recommend First-Line Biologics for Some Patients
New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
kfuhlert / Pixabay

New Approval Gives Juvenile Idiopathic Arthritis Patients More Options

On November 26, 2018, the FDA approved a new autoinjector for individuals with severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular or systemic juvenile idiopathic arthritis (aged 2 and older). It's…

Continue Reading New Approval Gives Juvenile Idiopathic Arthritis Patients More Options